Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)

Iraq Balks at Joining OPEC Cuts
35:34 - Oil investors are playing it safe as OPEC tries to finalize its deal to limit output. More talks are planned this week but there are new doubts about the plan. Bloomberg's Ben Sharples reports on "Bloomberg Markets." (Source: Bloomberg)
  • The Effect of the Human Body on Trading
  • BBHO Tops Rinehart's Bid for Kidman Cattle Empire
  • Malaysia's Budget Targets Loyal Voters